-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Alzheimer's disease (AD), editor of WuXi AppTec's content team, is the most common neurodegenerative disease in the elderly.
In 2019, there were more than 35 million patients worldwide, most of whom were elderly over 60 years old.
AD not only deprives them of their memories, but also severely affects their cognition and self-care ability.
It not only has a profound negative impact on the individual patients, but also on their families, communities, and countries.
However, in the field of AD therapy development, since 2003, the US FDA has not approved any innovative drugs for the treatment of AD.
However, scientists have not stopped exploring innovative treatments for AD because of past failures.
At the 15th International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD 2021) held online today, Cognito Therapeutics announced that the company’s innovative digital therapy for the treatment of AD through acousto-optic stimulation is in phase 2 clinical trials.
Positive results were obtained in the trial.
After 6 months of treatment, the patient’s memory and cognitive decline rate was not only reduced by 83%.
Compared with the control group, AD-related brain atrophy was also reduced by 61%, which means This innovative treatment has the potential to change the course of AD disease.
The press release pointed out that this is the first digital therapy that can improve memory, cognition, daily function and reduce brain atrophy in AD patients.
Without injections and medicine, AD can be treated with LED light bulbs that flash at a certain frequency and sound stimulation.
This amazing-sounding treatment comes from the breakthrough discovery of Professor Lihui Cai from the Massachusetts Institute of Technology (MIT).
As early as 2016, her team published a paper in the top scientific journal "Nature", showing that in a mouse model of Alzheimer's disease, using LED lights to emit a special frequency of flashes can reduce the starch in the mouse brain Amyloid deposition is one of the hallmarks of AD brain, and it is also the target of many drug therapies under investigation.
Aducanumab, jointly developed by Biogen and Eisai, is currently undergoing FDA review and is a monoclonal antibody therapy designed to remove amyloid deposits in the brain.
Subsequently, Professor Lihui Cai’s team published papers in "Cell" and Neuron, which further clarified the mechanism of using acousto-optic stimulation to clear amyloid deposits in mouse models and improve the cognitive ability of mice.
Researchers have found that when combined use of acousto-optic stimulation with a frequency of 40 hertz (Hz), it can not only stimulate the response of microglia to help clear amyloid, but also maintain the number and health of nerve synapses.
▲40Hz sound stimulation and acousto-optic stimulation improve animal cognition and amyloid clearance in the mouse AD model (picture source: reference [2]).
It is gratifying to make these research breakthroughs in the mouse model.
Whether this strategy can achieve the same effect in humans is a more critical question.
Professor Lihui Cai co-founded Cognito Therapeutics to further promote the clinical development of this technology.
The sound and light stimulation therapy developed by the company received a breakthrough medical device designation from the US FDA last month.
▲Professor Cai Lihui (picture source: MIT official website) In this randomized controlled clinical trial called OVERTURE, 76 patients with mild to moderate AD over the age of 50 received a non-invasive acousto-optic stimulation at a frequency of 40 Hz at random , Or fake stimulation.
This treatment is done at home, and the course of treatment is one hour per day.
In the following 6 months, the researchers measured the patient’s ability of daily living (using the ADCS-ADL score), memory and cognitive abilities (using the MMSE score), and using MRI ( MRI) to assess changes in brain volume.
The results of the test showed that compared with the control group (n=20), the treatment group (n=33) reduced the rate of decline in the ability of daily living score by 84%, memory and cognitive decline by 83%, and brain atrophy and The rate of brain volume loss also slowed by 61%.
All these changes meet the statistical significance standard.
"These remarkable results provide a clinical proof of concept for our strategy, and the reduction in brain atrophy and brain volume loss means it has the potential to change the course of the disease.
" said Dr.
Tom Megerian, Chief Medical Officer of Cognito Therapeutics, "If these results can The repetition of large-scale key clinical trials will represent a major breakthrough in the field of Alzheimer's disease research!" Note: This article is intended to introduce medical and health research, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
Reference: [1] Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer's Disease.
Retrieved March 9, 2021, from https:// news/home/20210309005355/en[2] Martorell et al, (2019).
Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition.
Cell, https://doi.
org/10.
1016/j.
cell.
2019.
02.
014.
[3] Adaikkan et al, (2019).
Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection.
Neuron, https://doi.
org/10.
1016/j.
neuron.
2019.
04.
011[4] Alzheimer's association.
Retrieved March 9, 2021, from https://
In 2019, there were more than 35 million patients worldwide, most of whom were elderly over 60 years old.
AD not only deprives them of their memories, but also severely affects their cognition and self-care ability.
It not only has a profound negative impact on the individual patients, but also on their families, communities, and countries.
However, in the field of AD therapy development, since 2003, the US FDA has not approved any innovative drugs for the treatment of AD.
However, scientists have not stopped exploring innovative treatments for AD because of past failures.
At the 15th International Conference on Alzheimer’s and Parkinson’s Disease (AD/PD 2021) held online today, Cognito Therapeutics announced that the company’s innovative digital therapy for the treatment of AD through acousto-optic stimulation is in phase 2 clinical trials.
Positive results were obtained in the trial.
After 6 months of treatment, the patient’s memory and cognitive decline rate was not only reduced by 83%.
Compared with the control group, AD-related brain atrophy was also reduced by 61%, which means This innovative treatment has the potential to change the course of AD disease.
The press release pointed out that this is the first digital therapy that can improve memory, cognition, daily function and reduce brain atrophy in AD patients.
Without injections and medicine, AD can be treated with LED light bulbs that flash at a certain frequency and sound stimulation.
This amazing-sounding treatment comes from the breakthrough discovery of Professor Lihui Cai from the Massachusetts Institute of Technology (MIT).
As early as 2016, her team published a paper in the top scientific journal "Nature", showing that in a mouse model of Alzheimer's disease, using LED lights to emit a special frequency of flashes can reduce the starch in the mouse brain Amyloid deposition is one of the hallmarks of AD brain, and it is also the target of many drug therapies under investigation.
Aducanumab, jointly developed by Biogen and Eisai, is currently undergoing FDA review and is a monoclonal antibody therapy designed to remove amyloid deposits in the brain.
Subsequently, Professor Lihui Cai’s team published papers in "Cell" and Neuron, which further clarified the mechanism of using acousto-optic stimulation to clear amyloid deposits in mouse models and improve the cognitive ability of mice.
Researchers have found that when combined use of acousto-optic stimulation with a frequency of 40 hertz (Hz), it can not only stimulate the response of microglia to help clear amyloid, but also maintain the number and health of nerve synapses.
▲40Hz sound stimulation and acousto-optic stimulation improve animal cognition and amyloid clearance in the mouse AD model (picture source: reference [2]).
It is gratifying to make these research breakthroughs in the mouse model.
Whether this strategy can achieve the same effect in humans is a more critical question.
Professor Lihui Cai co-founded Cognito Therapeutics to further promote the clinical development of this technology.
The sound and light stimulation therapy developed by the company received a breakthrough medical device designation from the US FDA last month.
▲Professor Cai Lihui (picture source: MIT official website) In this randomized controlled clinical trial called OVERTURE, 76 patients with mild to moderate AD over the age of 50 received a non-invasive acousto-optic stimulation at a frequency of 40 Hz at random , Or fake stimulation.
This treatment is done at home, and the course of treatment is one hour per day.
In the following 6 months, the researchers measured the patient’s ability of daily living (using the ADCS-ADL score), memory and cognitive abilities (using the MMSE score), and using MRI ( MRI) to assess changes in brain volume.
The results of the test showed that compared with the control group (n=20), the treatment group (n=33) reduced the rate of decline in the ability of daily living score by 84%, memory and cognitive decline by 83%, and brain atrophy and The rate of brain volume loss also slowed by 61%.
All these changes meet the statistical significance standard.
"These remarkable results provide a clinical proof of concept for our strategy, and the reduction in brain atrophy and brain volume loss means it has the potential to change the course of the disease.
" said Dr.
Tom Megerian, Chief Medical Officer of Cognito Therapeutics, "If these results can The repetition of large-scale key clinical trials will represent a major breakthrough in the field of Alzheimer's disease research!" Note: This article is intended to introduce medical and health research, not a treatment plan recommendation.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
Reference: [1] Cognito Therapeutics Announces Positive Phase 2 Results as First Digital Therapeutic to Improve Memory, Cognition, Functional Abilities and Reduce Brain Atrophy in Alzheimer's Disease.
Retrieved March 9, 2021, from https:// news/home/20210309005355/en[2] Martorell et al, (2019).
Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition.
Cell, https://doi.
org/10.
1016/j.
cell.
2019.
02.
014.
[3] Adaikkan et al, (2019).
Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection.
Neuron, https://doi.
org/10.
1016/j.
neuron.
2019.
04.
011[4] Alzheimer's association.
Retrieved March 9, 2021, from https://
